Fast-read summaries of the latest findings, clinical updates, and research notes — curated from the frontlines of oncology science.
New 2026 research in Cells shows ivermectin prevents stress granule dissolution in neuroblastoma cells by suppressing de novo Hsp70 protein synthesis, revealing a novel anticancer mechanism.
A 2026 in-vitro study on MCF-7 breast cancer cells evaluates curcumin plus cisplatin synergy using AgNOR staining and machine learning classification.
University of Florida oncologists publish a September 2026 case report of metastatic melanoma with initial ctDNA decline during self-directed ivermectin and fenbendazole use, followed by progression. Authors emphasize spontaneous regression as at least as plausible as drug effect.
Preclinical study (Biomed Pharmacother, Sep 2026) shows disulfiram disrupts ALDH-mediated redox homeostasis to deplete PARPi-induced dormant reservoirs in high-grade serous ovarian cancer cell lines, durably suppressing clonogenic recovery. In-vitro evidence only; no human trial data.
A new 2026 study from McGill University reveals how ivermectin inhibits stress granule clearance in neuroblastoma by blocking de novo Hsp70 synthesis — a novel mechanism that may inform ivermectin-based anticancer strategies.
A preclinical study shows curcumin formulated as a PVP K30 solid dispersion dramatically enhances solubility and synergizes with common chemotherapy drugs against lung cancer cells.
A new curcumin-loaded nanocarrier uses glucose oxidase and an iron-copper metal-organic framework to create a self-amplifying autophagy-ferroptosis cycle that enhances tumor suppression in preclinical cell and animal models.
A new 2026 preclinical study in rats finds that curcumin and baicalein together significantly reduce mammary tumor burden, inflammation, and oxidative stress. The combination outperformed either compound alone, but human data is not yet available.
New 2026 research demonstrates curcumins epigenetic mechanism against pancreatic cancer via DNMT3B inhibition, miR-29b restoration, and ROS-driven apoptosis.
A 577-patient randomized trial shows curcumin significantly suppresses growth of recurrent colorectal adenomas ≥6 mm after endoscopic polypectomy, with minimal side effects over 2 years.
A 2026 study in Journal of Biomaterials Applications demonstrates a gelatin hydrogel loaded with methylene blue as a photodynamic therapy platform for gliosarcoma, achieving 95% cell death and 95.35% encapsulation efficiency.
A new August 2026 in vitro study finds that combining mebendazole with flutamide produces synergistic antiproliferative effects in prostate cancer cell lines, reducing the required flutamide dose while increasing apoptosis. The evidence is entirely preclinical.
A Japanese multicenter RCT of 577 patients found that curcumin (180 mg twice daily) significantly suppressed the growth of recurrent colorectal adenomas over 2 years.
A novel bifunctional macromolecular system combining curcumin with selenium-loaded bovine serum albumin triggers programmed cell death (apoptosis) in lung adenocarcinoma cells in vitro.
An August 2026 study in RSC Advances reports silk-fibroin artemisinin nanoparticles reduced melanoma cell viability to approximately 23% in preclinical testing. This is early in vitro evidence only.
A 2026 preclinical study in Cells demonstrates that curcumin enhances mitotane's anti-tumor effects in adrenocortical carcinoma through metabolic rewiring and liver protection.
A 2026 study in Bioorganic Chemistry demonstrates curcumin's distinct anti-tumor effects in liver cancer through NRF1α/NRF2 metabolic reprogramming.
A 2026 study from Queen's University Belfast reports a 3D-printed microneedle system that co-delivers curcumin and 5-FU for localized skin cancer therapy. The platform achieves >95% insertion efficiency and controlled biphasic release in preclinical characterization.
A 2026 study in Bioorganic Chemistry reveals that curcumin suppresses liver cancer primarily through NRF1α stabilization, with synthetic lethality in NRF1α-deficient tumors.
A 2026 study in Journal of Gastroenterology demonstrates curcumin blocks Fusobacterium nucleatum-driven esophageal squamous cell carcinoma by inhibiting the TLR4/MYD88/TRIF/STAT3 axis, suppressing tumor growth and restoring chemotherapy sensitivity in cell and animal models.
Researchers used multi-omics profiling and computational drug screening to identify ivermectin as a potential candidate for hepatocellular carcinoma. The study is in silico and requires experimental validation.
A 2026 computational study investigates encapsulating fenbendazole within cucurbituril nanocarriers to improve aqueous solubility and stability for potential cancer therapy applications.
A 2026 preclinical study uses optical coherence tomography to evaluate mebendazole's anticancer activity in ovarian cancer spheroids, including cisplatin-resistant models.
A 73-year-old breast cancer patient developed life-threatening neurotoxicity after self-administering high-dose ivermectin. She recovered fully after 48 hours of intensive care. The case highlights the dangers of unsupervised off-label use.
A 2026 in-vitro study in Scientific Reports describes a sugar-linked curcumin complex that selectively targets glucose transporters overexpressed in breast cancer cells, achieving cytotoxicity with an IC50 of 7.51 μg/mL.
A 2026 study shows platelet-membrane-coated ivermectin nanocrystals selectively target triple-negative breast cancer cells and enhance immune infiltration in preclinical models. This biomimetic approach addresses solubility and toxicity barriers.
A 2026 PLOS One study showed ivermectin suppresses estrogen receptor, HER2, and TGF-β signaling in endocrine-resistant breast cancer cells, suggesting potential to prevent or reverse resistance.
The NIH has registered a new Phase 2 clinical trial (NCT07487805, ICONIC) to evaluate ivermectin combined with immune checkpoint inhibitors in adult solid tumor patients. The trial is not yet recruiting, with an estimated start of September 2026.
A 2026 study in the Asian Pacific Journal of Cancer Prevention tested a synthetic curcumin derivative (CCA-1.1) in a 3D spheroid model of triple-negative breast cancer, showing dose-dependent inhibition and altered EMT markers.
A 2026 Oncology Reports study shows mebendazole enhances chemotherapy and promotes macrophage polarization from M2 to M1 in patient tumor models and a mouse colon cancer model.
A 2026 Scientific Reports study demonstrates that a microbial levan enhances hepatic retention and antitumor activity of a PEGylated benzimidazole-curcumin nanocomplex in experimental liver cancer.
A 2026 Frontiers in Oncology case report documents a patient with metastatic HR+ breast cancer who achieved near-complete response using metabolic therapy combined with repurposed drugs.
Mebendazole inhibits PELI3 E3 ubiquitin ligase expression in HCC827 and A549 non-small cell lung cancer cells, increasing TRADD protein levels and restoring proapoptotic autophagy.
A new 2026 review in Pharmaceutics proposes curcumin as a molecular synergy amplifier whose clinical utility depends on mechanistic complementarity and pharmacokinetic synchronization with co-administered therapies.
Mebendazole shows modest single-agent cytotoxicity in patient-derived AML, ovarian, colorectal and renal cancer cells, but enhances irinotecan and cisplatin effects. In a mouse CT26 colon cancer model, mebendazole promotes M2→M1 macrophage polarization.
A 2026 review in Molecular Biology Reports summarizes preclinical evidence that monensin, a veterinary ionophore, demonstrates antitumor activity across breast, prostate, pancreatic, ovarian, renal, liver, thyroid, and brain malignancies.
A 2026 case report in Cureus documents severe drug-induced liver injury in a 65-year-old prostate cancer patient who self-administered veterinary fenbendazole and ivermectin for three months.
A July 2026 study in Apoptosis demonstrates that artemisinin-loaded liposomes suppress breast cancer metastasis and induce apoptosis by modulating the TIGIT/CD155 immune checkpoint axis in 4T1 cell and mouse models.
A 2026 study combines network pharmacology, molecular dynamics, and in vitro experiments to explore how curcumin targets gastric cancer pathways.
A 2026 systematic review evaluates mebendazole's preclinical and clinical evidence across glioblastoma, medulloblastoma, and meningioma, highlighting translational gaps.
A 2026 conceptual review highlights monepantel's emerging anticancer mechanisms, including mTOR inhibition and autophagy induction, based on preclinical evidence.
A novel methylene blue derivative, 1,9-dimethyl methylene blue, shows promise as a photosensitizer for photodynamic therapy against oropharyngeal cancer.
A synthetic curcumin analog called E145 shows potent anticancer activity by blocking NF-κB signaling in breast cancer cells and reducing lung metastasis in mice.
Curcumin suppresses NLRP3 inflammasome activation in tumor-associated macrophages, reducing inflammatory signals that drive breast cancer progression.
A 2026 preclinical study shows nitazoxanide, an FDA-approved antiparasitic drug, triggers ferroptosis in TNBC cells by disrupting iron homeostasis and degrading the beta-catenin/GPX4 axis. The findings are based on in vitro and zebrafish xenograft data only.
A 2026 preclinical study found that the synthetic curcumin analogue B-155 demonstrates significantly greater cytotoxicity than natural curcumin in SKOV3 ovarian cancer cells, with effects including G2/M cell-cycle arrest, apoptosis, and p38 MAPK binding. The study is limited to in vitro data.
In a 2026 preclinical study using patient-derived 3D spheroids, mebendazole prevented cellular invasion in 89% of meningioma samples by disrupting Rho-GTPase-mediated microtubule function. This is early laboratory evidence, not a clinical trial.
A 2026 preclinical study in the International Journal of Pharmaceutics developed a curcumin-releasing hydrogel that, when applied after prostate cancer surgery, suppressed tumor regrowth and reduced lymph node metastasis by maintaining high local drug concentration. Animal-model evidence only.
A 2026 preclinical study shows mebendazole impairs nucleotide metabolism enzymes in gastric cancer cells, causing cell cycle arrest and antiproliferative activity comparable to 5-FU with lower toxicity to normal cells. Laboratory evidence only.
A 2026 preclinical study shows curcumin induces ferroptosis in papillary thyroid cancer cells by downregulating GPX4, suppressing tumour growth in mice without organ toxicity.
